knowledge -WSS

knowledge

author：leisure time 2025-10-02 11:08:21 - browse：541

CHICAGO — The Food and Drug Administration’s top oncologist reiterated that the agency doesn’t want drugmakers applying for approval with data from trials solely run in a single country such as China, but instead wants to see companies conducting studies across the world.

The comments by Richard Pazdur, director of the FDA’s Oncology Center of Excellence, came as more drugmakers report data from China, with Miami-based Summit Therapeutics earlier this week announcing that its investigational drug beat Merck’s blockbuster Keytruda in a head-to-head non-small cell lung cancer study in China.

It’s not a blanket policy, and the agency would assess each company’s submission to see how applicable the data are to the U.S. population, but in general, “I am pro multi-regional trials,” Pazdur said Friday at STAT@ASCO, STAT’s event at the American Society of Clinical Oncology annual meeting.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Male doctors called my cancer incurable. A female doctor showed it wasn't

WSS

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

Nonprofit, backed by Microsoft, to certify AI tools in health care

Congress must reauthorize a committee to support older Americans

CRISPR pioneers react to Casgevy, first gene

FDA early review: GLP

American taxpayers paid $1.8 trillion in health care costs in 2022

focus

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Does Paxlovid work in people vaccinated against Covid

Peter Hotez and the public health issue of online harassment

NYU radiologists take on the challenge of expensive MRI machines

Heart attack and stroke risk calculators need revising

Surge of respiratory disease in China has likely explanation

How one medical school became remarkably diverse

Hospital chaplains balance Covid safety with patients’ spiritual needs

Wildfire smoke exposes gaps in outdoor worker protections

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

explore

FDA early review: GLP

Stories you might have missed in 2023: health, science, medicine

U.K. considers world's first use of meningitis vaccine to address gonorrhea

David Sabatini, ex

Ransomware attacks on hospitals: Study outlines patient impact

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

focus

Wikipedia

hotspot

Wikipedia